Hidradenitis Suppurativa study: Radiated axilla
Official title Radiotherapy for Refractory Hidradenitis Suppurativa
ClinicalTrials.gov ID: NCT07414550
What this study is testing
- What it's testing
- The study wants to find out whether radiotherapy can reduce the number of painful nodules, abscesses, and draining tracts in one armpit, and whether it improves quality of life, pain, and overall symptoms.
- Who it's for
- Adults (18+) with moderate to severe hidradenitis suppurativa that has not responded well to other treatments.
- What's involved
- Participants will receive radiotherapy on one armpit while the other armpit receives standard care. They will have a skin exam, fill out surveys, and may have a biopsy at the start and after treatment. They will attend several radiation sessions over five weeks and two follow‑up visits for skin checks and surveys.
- Time commitment
- The study lasts about 5 weeks of treatment plus follow‑up visits, with a total of roughly 7 clinic visits over the course of the study.
- Time commitment: about 5 weeks
Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Male or female people between the age of 18 or older with moderate or severe HS (Hurley Stage II or III) with bilateral axillary disease of...
- Patients on topical and/or systemic HS medications for at least 1 month will continue maintenance treatment throughout the study period as per...
- Patients willing and able to provide informed consent
You likely can't join if
- Pregnancy - Women of childbearing potential must use trial approved birth control and obtain a negative pregnancy test 7 days prior to radiotherapy...
- Severe autoimmune conditions including lupus, scleroderma and mixed connective tissue disease
- Poorly controlled diabetes per physician discretion, HIV, Hepatitis B/C.
- Prior therapeutic radiotherapy.
- Active malignancy.
- Contraindication to radiotherapy as determined by treating radiation oncologist.
See the full eligibility criteria
- Male or female people between the age of 18 or older with moderate or severe HS (Hurley Stage II or III) with bilateral axillary disease of approximately equivalent disease severity will be included.
- Patients on topical and/or systemic HS medications for at least 1 month will continue maintenance treatment throughout the study period as per standard of care.
- Patients willing and able to provide informed consent
- Pregnancy - Women of childbearing potential must use trial approved birth control and obtain a negative pregnancy test 7 days prior to radiotherapy CT simulation.
- Severe autoimmune conditions including lupus, scleroderma and mixed connective tissue disease
- Poorly controlled diabetes per physician discretion, HIV, Hepatitis B/C.
- Prior therapeutic radiotherapy.
- Active malignancy.
- Contraindication to radiotherapy as determined by treating radiation oncologist.
- Patients who began new systemic treatment for their HS \<1 month prior to enrollment in trial
- History of photosensitivity disorders or prior radiation sensitization syndromes
- Any contraindication to radiotherapy as determined by the treating radiation oncologist.
The study team makes the final eligibility decision.
Where it is enrolling
- Cherry Hill, New Jersey, United States
- Philadelphia, Pennsylvania, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The study runs about 5 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Cherry Hill, New Jersey, United States; Philadelphia, Pennsylvania, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.